<DOC>
	<DOC>NCT02320032</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.</brief_summary>
	<brief_title>An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Has stable schizophrenia or schizoaffective disorder Has demonstrated ability to tolerate aripiprazole Has been on a stable antipsychotic medication regimen without any changes for at least 2 months prior to screening Has a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive Additional criteria may apply Is pregnant, breastfeeding, or is planning to become pregnant during the study period Has received aripiprazole lauroxil or IM depot aripiprazole within 6 months, or other longacting, injectable antipsychotic medication within 3 months Is a danger to himself/herself at screening or upon admission Has a history of or positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C Has a positive urine drug screen at screening or Day 1 Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Aripiprazole lauroxil</keyword>
	<keyword>ALKS 9072</keyword>
</DOC>